{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
NCT04718792: Phase 2 Interventional Active, not recruiting Alcohol Use Disorder (AUD)
(2023)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Once ingested, psilocybin is rapidly metabolized to the psilocin, which then acts on serotonin receptors in the brain. Psilocybin was identified as the active hallucinogenic compound in magic mushrooms in 1959, but humans have used assorted psilocybin mushrooms in religious ceremonies since prehistoric times. In the 1960's psilocybin was marketed for use as a treatment for various psychoses, however, it was withdrawn from the market when the regulatory environment changed. Recently there has been as renewed interest in studying the medicinal uses of psilocybin for treatment of anxiety, depression, migraine headaches, addictions, and other neuropsychiatric conditions.
Status:
Investigational
Source:
NCT02079246: Phase 3 Interventional Completed Alzheimer's Disease
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Idalopirdine (Lu AE58054) is a Serotonin 6 receptor (5-HT6) antagonist. Idalopirdine exrets good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. In rats idalopirdine potentiates the effects of acetylcholinesterase inhibitor donepezil on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Such potentiation could contribute to the procognitive effects of idalopirdine observed in donepezil-treated Alzheimer's disease patients. The compound is being developed by Lundbeck as an adjunctive therapy with acetylcholinesterase inhibitor donepezil, and is in phase III development for the treatment of Alzheimer's disease in multiple countries worldwide. A phase II trial for the treatment of cognitive impairment associated with schizophrenia was conducted; however no recent reports of development for idalopirdine have been identified.
Class (Stereo):
CHEMICAL (ACHIRAL)
Ripazepam (CI 683 or pyrazapon) is a pyrazolodiazepine that has anxiolytic effects. It is related to certain benzodiazepines such as zolazepam. In animal studies, it showed anxiolytic effects without sedative or depressant effects. In rats, it did not elicit a tumorigenic potential. Although ripazepam was found significantly superior to placebo and was well tolerated in neurotic patients, it has never been marketed for clinical use.
Status:
Investigational
Source:
INN:disobutamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Disobutamide suppresses ventricular arrhythmias in several in vivo animal models. In particular, disobutamide suppressed ventricular arrhythmias in ouabain-toxic dogs and in dogs in which myocardial infarction. Clear cytoplasmic vacuolation associated with disobutamide is an example of a remarkable morphologic change not associated with apparent overt toxicity based on various functional tests. Clinically in the dog if vacuolation was associated with cell injury, one might expect a chronic debilitating condition as seen in the case of many spontaneous genetic storage diseases. Chronic heart failure or a gastrointestinal motility disorder might occur as a result of the changes in the musculature of coronary arteries or gastrointestinal wall, respectively. Disobutamide, because of its apparent low toxicity, can be recommended as useful for investigations aimed at determining the borderline between physiologic limits and toxicity of intracellular drug storage and for advancing knowledge of mechanisms involved in xenobiotics entry and storage in cells. Disobutamide was withdrawn from clinical testing when clear cytoplasmic vacuoles were found in the rat and dog during toxicity studies. Disobutamide induced vacuoles in all cell types except rat leukaemia. The drug induced cell death and reduction in confluency or cell count in cultures of all cell types except rat carcinoma and rabbit aorta muscle.
Class (Stereo):
CHEMICAL (ACHIRAL)
Thyromedan is a thyroalkanoic acid derivative with hypocholesterolemic activity. In clinical trials, Thyromedan in daily doses of 8 to 32 mg caused a decrease in serum cholesterol levels. The serum total triglycerides and the α- and β-lipoprotein partition of cholesterol and triglycerides were unaffected.
Status:
Investigational
Source:
NCT00454103: Phase 1/Phase 2 Interventional Completed Adrenal Tumor
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iodometomidate I-123, R- (also known as ) is phenylethylimidazole derivative studied as a diagnostic agent for adrenal imaging. Iodometomidate is a highly suitable tracer combining specific uptake in adrenocortical tissue with far lower radiation exposure compared to norcholesterol scintigraphy. Phase III clinical trial for Adrenal Gland Neoplasms imaging is currently ongoing.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Letimide is a new analgesic. It is a cyclic derivative of a salicylamide. The analgesic effect of this drug as determined in rats showed a higher potency than aspirin, but was without anti-inflammatory and antipyretic activity. Letimide is not a genotoxic agent according to the cytogenetic damage observed in vivo and in vitro, and would seem to justify other preclinical and clinical studies to confirm its lack of toxicity. Known adverse effects are headache and dizziness.
Class (Stereo):
CHEMICAL (RACEMIC)
Modecainide is a benzanilide derivative patented by American pharmaceutical company Bristol-Myers Co. as type Ic antiarrhythmic agent. Modecainide is a major metabolite of Encainide, a class Ic antiarrhythmic, with comparable antiarrhythmic activity. Modecainide is never marketed because of its frequent proarrhythmic side effects.
Status:
Investigational
Source:
Diabetes Care. 1984;7(1):19-24.: Not Applicable Human clinical trial Completed Diabetes Mellitus, Type 2/blood
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Halofenate (MK-185) was invented as a hypolipidemic and hypouricemic agent. It was shown that halofenate lower serum triglycerides and uric acid in patients with a variety of hyperlipidemias. Treatment of dyslipidemic type 2 diabetic patients also showed triglyceride lowering and, surprisingly, significant reductions in plasma glucose and insulin. Halofenate is a selective PPAR-γ modulator (SPPARγM). SPPARγMs are believed to bind in distinct manners to the ligand-binding pocket of PPAR-γ, leading to altered receptor conformational stability and resulting in distinct patterns of gene expression. Thus, was suggested that halofenate hold promising therapeutic potential in the treatment of type 2 diabetes, without the side effects. However, information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:milipertine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Milipertine was studied in patients with severe schizophrenia. Information about the current use of the drug is not available.
